A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway

Toshihiro Nagato; Esteban Celis

doi:10.4161/onci.28440

A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway

Toshihiro Nagato, Esteban Celis

Oncology Research

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

Original language	English (US)
Article number	e28440
Journal	OncoImmunology
Volume	3
Issue number	5
DOIs	https://doi.org/10.4161/onci.28440
State	Published - 2014

Keywords

Cancer immunotherapy
Colon cancer
Lung cancer
Melanoma
PD-1
PD-L1
Poly-IC

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/onci.28440

Cite this

@article{5126d2744f194e949a0bcf9358bf66bd,

title = "A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway",

abstract = "A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.",

keywords = "Cancer immunotherapy, Colon cancer, Lung cancer, Melanoma, PD-1, PD-L1, Poly-IC",

author = "Toshihiro Nagato and Esteban Celis",

note = "Funding Information: This work was supported by NIH grants R01CA136828 and R01CA157303 to E.C.",

year = "2014",

doi = "10.4161/onci.28440",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - A novel combinatorial cancer immunotherapy

T2 - Poly-IC and blockade of the PD-1/PD-L1 pathway

AU - Nagato, Toshihiro

AU - Celis, Esteban

N1 - Funding Information: This work was supported by NIH grants R01CA136828 and R01CA157303 to E.C.

PY - 2014

Y1 - 2014

N2 - A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

AB - A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

KW - Cancer immunotherapy

KW - Colon cancer

KW - Lung cancer

KW - Melanoma

KW - PD-1

KW - PD-L1

KW - Poly-IC

UR - http://www.scopus.com/inward/record.url?scp=84904045263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904045263&partnerID=8YFLogxK

U2 - 10.4161/onci.28440

DO - 10.4161/onci.28440

M3 - Article

AN - SCOPUS:84904045263

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 5

M1 - e28440

ER -

A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this